Intraventricular immunovirotherapy; a translational step forward.
Intraventricular immunovirotherapy; a translational step forward.
复制标题
作者：
肿瘤内工程1型单纯疱疹病毒(HSV)的溶瘤病毒治疗已被证明是安全的，在最近的临床试验中对儿童和成人高级别胶质瘤都有良好的疗效。然而，这种方法不包括在手术中无法触及和/或有口才的脑区有肿瘤的患者。目前的分娩方法也无法接触/治疗那些患有脊髓转移性疾病和/或软脑膜疾病的患者。最近的一项临床前研究已经为脑室内注射OHSV的临床翻译铺平了道路，确定并减轻了与这一路线相关的毒性，以利于对播散性髓母细胞瘤的小鼠模型的治疗。这项工作最终可能针对难治性疾病，并为临床相关免疫病毒疗法的重复剂量提供一种可行的选择，G207。
Oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease. A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207.